BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
Publication|Articles|May 16, 2025
- Pharmaceutical Executive: May 2025
- Volume 45
- Issue 4
Pharmaceutical Executive: May 2025 Interactive Digital Edition
View the Pharmaceutical Executive May 2025 issue in an interactive format.
Advertisement
Articles in this issue
over 1 year ago
Your Voice Boxover 1 year ago
Pharm Exec's 2025 State of the Industry Surveyover 1 year ago
Reshema Kemps-Polanco: Taking Risks for Greater Rewardover 1 year ago
Earned Media and ASCO: Provide Context Beyond the Dataover 1 year ago
How Does the Shift to Early-Stage M&A Change Due Diligence?over 1 year ago
The Three Pillars of Pharma’s New Commercial Modelover 1 year ago
Revenue Optimization: The Money Matters—That Matter Mostover 1 year ago
Bridging the Gap: A Large Pharma BlueprintAdvertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Rebuilding Clinical Data Workflows for the AI Era
3
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5